Weekly Policy Update: Action on Two Bills and Advocacy in DC

UNDER THE GOLD DOME This week, HB18-1135: Extend Advanced Industry Export Acceleration Program passed the Colorado House of Representatives and next week it moves to the Senate. This bill extends the...

Learn More

Weekly Policy Update: CBSA Takes Positions on Additional Bills, Transparency News, and China Tariffs

UNDER THE DOME The Colorado BioScience Association took formal positions on three bills this week. With 18 working days left of session we continue to evaluate and make recommendations on legislation...

Learn More

Weekly Policy Update: CO House Votes on Prescription Drug Price Transparency Bill Monday!

Colorado House Votes next week on Prescription Drug Price Transparency Bill (HB18-1260) CBSA continues to advocate against House Bill 1260, Prescription Drug Price Transparency. The bill could stifle...

Learn More

Weekly Policy Update: Colorado Budget and Forecast, plus a True Transparency update

CO State Budget & March Forecast Transportation, Education, PERA, and opioid addiction are a few of the areas that will receive funding in the $28.9 billion state budget package passed by the Colo...

Learn More

Weekly Policy Update: Advocacy Around Drug Transparency Issues, an Opportunity To Be Heard By the Next Governor, and the Omnibus Spending Bill

This week CBSA testified in opposition to House Bill 1009, Diabetes Drug Pricing Transparency Act 2018. The bill was heard in the House Health, Insurance and Environment Committee and passed on a part...

Learn More

Weekly Policy Update: Continuing the Transparency Advocacy and a Business Guide for the Governor

CBSA Continues to Advocate in Opposition to House Bill 1260, Prescription Drug Price Transparency As reported last week, House Bill 1260, Prescription Drug Price Transparency passed on a party line vo...

Learn More

Weekly Policy Update: Prescription Drug Price Transparency

Transparency at the Colorado State Capitol This week CBSA testified in opposition to House Bill 1260, Prescription Drug Price Transparency. The bill was heard in the House Health, Insurance and Enviro...

Learn More

Weekly Policy Update: House Bill 1260 Prescription Drug Transparency, plus the Advamed Fly-In in Washington, D.C.

Urge a NO Vote on HB 1260, Prescription Drug Price Transparency This week CBSA opposed a new bill introduced by the Colorado House that could adversely impact the Colorado bioscience industry, Ho...

Learn More

Weekly Policy Update: Positions on three bills, true transparency, and a visit to D.C.

UNDER THE DOME The Colorado BioScience Association took formal positions on three bills this week and we continue to evaluate and make recommendations on legislation being introduced. Outlined below a...

Learn More

Weekly Policy Update: True Transparency and Medicare Stakeholder Input

CBSA promotes the interests of more than 725 bioscience companies and their 30,000 employees. We work every day to create an innovation-friendly business environment ensuring that as an industry we de...

Learn More